ANIP Stock Analysis
AN
Uncovered
ANI Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
1.231
Dividend yield
—
Shares outstanding
17.465 B
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 600 full-time employees. The company went IPO on 2000-05-04. The firm is focused on developing and manufacturing niche oncology products (anti-cancer). The company has a commercial portfolio of over 101 products with a variety of indications and a portfolio of pipeline products. The firm owns the facility, which includes oral solid dose and liquid manufacturing and packaging, warehouse facilities, analytical, stability, and microbiological laboratory space, and employee office and mechanical space. The company also owns a manufacturing facility that includes oral solid dose manufacturing and packaging for pharmaceutical products. Its four pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, one is located in East Windsor, New Jersey and one is located in Oakville, Ontario.